Logo image of IRD

OPUS GENETICS INC (IRD) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IRD - US67577R1023 - Common Stock

2.17 USD
+0.03 (+1.4%)
Last: 1/14/2026, 8:00:03 PM
2.13 USD
-0.04 (-1.84%)
After Hours: 1/14/2026, 8:00:03 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IRD. IRD was compared to 528 industry peers in the Biotechnology industry. IRD has a bad profitability rating. Also its financial health evaluation is rather negative. IRD is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • IRD had negative earnings in the past year.
  • In the past year IRD has reported a negative cash flow from operations.
  • In the past 5 years IRD reported 4 times negative net income.
  • In the past 5 years IRD reported 4 times negative operating cash flow.
IRD Yearly Net Income VS EBIT VS OCF VS FCFIRD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

  • The Return On Assets of IRD (-188.81%) is worse than 87.12% of its industry peers.
  • IRD has a Return On Equity of -1143.00%. This is in the lower half of the industry: IRD underperforms 79.55% of its industry peers.
Industry RankSector Rank
ROA -188.81%
ROE -1143%
ROIC N/A
ROA(3y)-46.02%
ROA(5y)-98.94%
ROE(3y)-68.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IRD Yearly ROA, ROE, ROICIRD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

  • IRD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IRD Yearly Profit, Operating, Gross MarginsIRD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

2

2. Health

2.1 Basic Checks

  • IRD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IRD has been increased compared to 1 year ago.
  • IRD has more shares outstanding than it did 5 years ago.
  • IRD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IRD Yearly Shares OutstandingIRD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
IRD Yearly Total Debt VS Total AssetsIRD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • IRD has an Altman-Z score of -6.25. This is a bad value and indicates that IRD is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -6.25, IRD is doing worse than 64.39% of the companies in the same industry.
  • IRD has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.18, IRD is doing worse than 64.96% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z -6.25
ROIC/WACCN/A
WACC8.82%
IRD Yearly LT Debt VS Equity VS FCFIRD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 1.23 indicates that IRD should not have too much problems paying its short term obligations.
  • IRD has a Current ratio of 1.23. This is amonst the worse of the industry: IRD underperforms 84.09% of its industry peers.
  • IRD has a Quick Ratio of 1.23. This is a normal value and indicates that IRD is financially healthy and should not expect problems in meeting its short term obligations.
  • IRD has a Quick ratio of 1.23. This is amonst the worse of the industry: IRD underperforms 82.95% of its industry peers.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.23
IRD Yearly Current Assets VS Current LiabilitesIRD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

7

3. Growth

3.1 Past

  • IRD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.85%, which is quite impressive.
  • IRD shows a strong growth in Revenue. In the last year, the Revenue has grown by 74.60%.
  • Measured over the past years, IRD shows a very strong growth in Revenue. The Revenue has been growing by 165.10% on average per year.
EPS 1Y (TTM)23.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.79%
Revenue 1Y (TTM)74.6%
Revenue growth 3Y165.1%
Revenue growth 5YN/A
Sales Q2Q%-20.38%

3.2 Future

  • IRD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.10% yearly.
  • IRD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 39.65% yearly.
EPS Next Y37.05%
EPS Next 2Y27.28%
EPS Next 3Y16.92%
EPS Next 5Y11.1%
Revenue Next Year46.95%
Revenue Next 2Y40.3%
Revenue Next 3Y31.21%
Revenue Next 5Y39.65%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
IRD Yearly Revenue VS EstimatesIRD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M 250M
IRD Yearly EPS VS EstimatesIRD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IRD. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IRD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRD Price Earnings VS Forward Price EarningsIRD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IRD Per share dataIRD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

  • A more expensive valuation may be justified as IRD's earnings are expected to grow with 16.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.28%
EPS Next 3Y16.92%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for IRD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

OPUS GENETICS INC

NASDAQ:IRD (1/14/2026, 8:00:03 PM)

After market: 2.13 -0.04 (-1.84%)

2.17

+0.03 (+1.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-30
Inst Owners21.31%
Inst Owner ChangeN/A
Ins Owners6.33%
Ins Owner Change-22.99%
Market Cap149.64M
Revenue(TTM)14.63M
Net Income(TTM)-68.20M
Analysts81.43
Price Target7.96 (266.82%)
Short Float %1.25%
Short Ratio1.24
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-24.18%
Min EPS beat(2)-90.4%
Max EPS beat(2)42.04%
EPS beat(4)3
Avg EPS beat(4)-7.07%
Min EPS beat(4)-90.4%
Max EPS beat(4)42.04%
EPS beat(8)3
Avg EPS beat(8)-59.5%
EPS beat(12)5
Avg EPS beat(12)-24%
EPS beat(16)8
Avg EPS beat(16)-16.12%
Revenue beat(2)0
Avg Revenue beat(2)-15.16%
Min Revenue beat(2)-29.45%
Max Revenue beat(2)-0.87%
Revenue beat(4)2
Avg Revenue beat(4)12.9%
Min Revenue beat(4)-29.45%
Max Revenue beat(4)42.31%
Revenue beat(8)3
Avg Revenue beat(8)-8.15%
Revenue beat(12)6
Avg Revenue beat(12)22.35%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.74%
PT rev (3m)-2.5%
EPS NQ rev (1m)6.79%
EPS NQ rev (3m)3.92%
EPS NY rev (1m)3.25%
EPS NY rev (3m)-20.27%
Revenue NQ rev (1m)-8.66%
Revenue NQ rev (3m)-18.53%
Revenue NY rev (1m)-1.83%
Revenue NY rev (3m)-8.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.23
P/FCF N/A
P/OCF N/A
P/B 25.08
P/tB 25.08
EV/EBITDA N/A
EPS(TTM)-0.83
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0.21
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -188.81%
ROE -1143%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.02%
ROA(5y)-98.94%
ROE(3y)-68.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.23
Altman-Z -6.25
F-Score2
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.79%
EPS Next Y37.05%
EPS Next 2Y27.28%
EPS Next 3Y16.92%
EPS Next 5Y11.1%
Revenue 1Y (TTM)74.6%
Revenue growth 3Y165.1%
Revenue growth 5YN/A
Sales Q2Q%-20.38%
Revenue Next Year46.95%
Revenue Next 2Y40.3%
Revenue Next 3Y31.21%
Revenue Next 5Y39.65%
EBIT growth 1Y-25.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year128.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-242.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-242.06%
OCF growth 3YN/A
OCF growth 5YN/A

OPUS GENETICS INC / IRD FAQ

Can you provide the ChartMill fundamental rating for OPUS GENETICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to IRD.


Can you provide the valuation status for OPUS GENETICS INC?

ChartMill assigns a valuation rating of 0 / 10 to OPUS GENETICS INC (IRD). This can be considered as Overvalued.


How profitable is OPUS GENETICS INC (IRD) stock?

OPUS GENETICS INC (IRD) has a profitability rating of 0 / 10.


What is the financial health of OPUS GENETICS INC (IRD) stock?

The financial health rating of OPUS GENETICS INC (IRD) is 2 / 10.